Expert Interview
Discussing the Phase 2/3 Orbit Study of Ultragenyx' Setrusumab (UX143) in treating Osteogenesis Imperfecta
Ticker(s): RARE, MREOInstitution: University of Sheffield
- Senior Clinical Lecturer in Musculoskeletal Genetics at University of Sheffield & Honorary Consultant Clinical Geneticist; Sheffield Children’s NHS Foundation Trust.
- Manages 200 patients with osteogenesis imperfecta
- Lead Consultant Bone Geneticist for the nationally-commissioned Osteogenesis Imperfecta service in England.
What are the key clinical trial results and efficacy outcomes observed in the development of UX143?
Added By: yusuff_adminHow does UX143 (setrusumab) compare to existing treatment options for Osteogenesis Imperfecta in terms of efficacy and safety?
Added By: yusuff_adminWhat is the anticipated market potential for UX143 in treating Osteogenesis Imperfecta?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
